The dynamically growing field of immunometabolism cemented how crucial intracellular and systemic metabolism is in the regulation of immune cells. Psoriasis, atopic dermatitis, and other skin diseases driven by immune dysregulation are hypothesized to be treatable by targeting specific metabolic pathways. Therefore, the aim is to characterize intralesional and systemic interdependencies of metabolic and immunological changes in different skin disease to identify and test new therapeutic approaches. The focus is on repurposing existing metabolic medications with a high safety profiles suitable for long-term management and their synergistic combination with existing therapies to improve quality of life especially in chronic conditions.
